SPRY Stock Overview
A biopharmaceutical company, develops treatments for severe allergic reactions. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ARS Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.18 |
| 52 Week High | US$18.51 |
| 52 Week Low | US$5.19 |
| Beta | 0.86 |
| 1 Month Change | -20.14% |
| 3 Month Change | -20.65% |
| 1 Year Change | 116.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 84.49% |
Recent News & Updates
ARS Pharmaceuticals: Demand Curve Is Key Unknown
Nov 20We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow
Sep 13
ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
Sep 06Recent updates
ARS Pharmaceuticals: Demand Curve Is Key Unknown
Nov 20We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow
Sep 13ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
Sep 06ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Jun 25We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Mar 18ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Nov 14Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
May 12Shareholder Returns
| SPRY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.1% | -3.6% | -2.4% |
| 1Y | 116.7% | -2.7% | 23.3% |
Return vs Industry: SPRY exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: SPRY exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| SPRY volatility | |
|---|---|
| SPRY Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SPRY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SPRY's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 26 | Rich Lowenthal | ars-pharma.com |
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
ARS Pharmaceuticals, Inc. Fundamentals Summary
| SPRY fundamental statistics | |
|---|---|
| Market cap | US$1.09b |
| Earnings (TTM) | -US$49.10m |
| Revenue (TTM) | US$2.57m |
423.1x
P/S Ratio-22.1x
P/E RatioIs SPRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRY income statement (TTM) | |
|---|---|
| Revenue | US$2.57m |
| Cost of Revenue | US$19.87m |
| Gross Profit | -US$17.30m |
| Other Expenses | US$31.80m |
| Earnings | -US$49.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | -673.71% |
| Net Profit Margin | -1,912.15% |
| Debt/Equity Ratio | 0% |
How did SPRY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ARS Pharmaceuticals, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Roanna Clarissa Ruiz | Leerink Partners LLC |
| Ryan Deschner | Raymond James & Associates |